

EC Declaration of Conformity

Manufacturer/ Supplier Information:	BioFire Diagnostics, LLC 515 Colorow Drive Salt Lake City, Utah 84108, USA Phone: 1-801-736-6354 regulatory@BioFireDX.com http://www.BioFireDX.com
--	---

We, BioFire Diagnostics, LLC, declare under our sole responsibility, that the product

BioFire® Blood Culture Identification 2 (BCID2) Panel (RFIT-ASY-0147)

meets the provisions of the European Directive 98/79/EC for *In Vitro* Diagnostic Medical Devices. The device is classified as an General In Vitro Diagnostic (IVD) Device. BioFire Diagnostics' quality system is registered to EN ISO 13485:2016.

The following relevant standards have been met:

EN ISO 13485:2016 Medical devices – Quality Management System – Requirements for regulatory purposes
EN ISO 14971:2012 Medical devices – Application of risk management to medical devices
EN 13641:2002 Elimination or reduction of risk of infection related to <i>in vitro</i> diagnostic reagents
EN 62366:2008 Medical devices-Application of usability engineering to medical devices
EN 13612:2002 Performance evaluation of <i>in vitro</i> diagnostic medical devices
EN ISO 23640:2015 <i>In vitro</i> diagnostic medical devices – Evaluation of stability of <i>in vitro</i> diagnostic reagents
EN ISO 15223-1:2016 Medical Devices – Symbols to be used with medical device labels, labeling and information to be supplied – Part 1: General requirements
EN ISO 18113-1:2011 <i>In vitro</i> diagnostic medical devices – Information supplied by the manufacturer (labeling) – Part 1: Terms, definition and general requirements
EN ISO 18113-2:2011 <i>In vitro</i> diagnostic medical devices – Information supplied by the manufacturer (labeling) – Part 2: <i>In vitro</i> diagnostic reagents for professional use

Technical documentation demonstrating compliance as described in Annex IV of the European Directive 98/79/EC is kept by the manufacturer and can be made available by the authorized representative in Europe - QARAD EC-REP BV, Pas 257, B-2440 Geel, Belgium.

The notified body for this product is BSI (Notified body #2797; Say Building, John M. Keynesplein 9, 1066 EP Amsterdam, Netherlands).

Salt Lake City, UT, USA
(Place and date of issue)

1 April 2020


Kristen Kanack
SVP of Regulatory and Clinical Affairs



515 Colorow Drive, Salt Lake City, UT 84108
phone 1-801-736-6354 | fax 1-801-588-0507

www.BioFireDX.com